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Abstract
Introduction: Triple negative breast cancer is associated with poorer prognosis and unresponsiveness to endocrine
and anti-HER2 directed agents. Despite emerging data supporting the use of polyADP-ribose polymerase (PARP)
inhibitors, complete and durable responses are rare and exploration of additional targeted therapies is needed.
Epidermal growth factor receptor (EGFR) is expressed in triple negative breast cancer and several clinical trials are
testing the role of anti-EGFR directed therapy. However, the rate of EGFR mutations is poorly defined. We,
therefore, sought to characterize EGFR mutations in triple negative breast cancers.
Methods: Seventy samples were randomly chosen from a cohort of 653 triple negative breast tumours for EGFR
mutation analysis. These samples were immunostained for EGFR protein expression and consisted of negatively stained
and positively stained cases. DNA was extracted from paraffin blocks and polymerase chain reaction was performed to
amplify exon regions 18 to 21 of the EGFR gene. Direct sequencing of the purified PCR products was performed.
Results: EGFR mutations were found in 8 of 70 samples (11.4%). Mutations were predominantly exon 19 deletions (4 of
70 samples, 5.7%), which clustered in the region spanning codons 746 to 759 within the kinase domain of EGFR. Two
types of exon 19 deletions were seen: a 15 nucleotide deletion (del E746-A750) (2 of 70 samples) and a 24 nucleotide
deletion (del S752 - I759) (2 of 70 samples). Other exon 19 mutations observed were the inversion of the
complementary strand (1 of 70 samples). Exon 21 mutations included missense substitution, L858R (1 of 70 samples)
and T847I (2 of 70 samples). Mutations observed were independent of EGFR protein expression determined by
immunohistochemical staining.
Conclusions: This study is among the first to document the presence and estimate the prevalence of EGFR mutations
in triple negative breast cancer. These findings have potential implications for the design of clinical trials involving anti-
EGFR directed therapy which currently do not select for patients based on presence of activating EGFR mutations,
which may hence be underpowered to detect significant benefit in unselected populations. More complete sampling
of EGFR mutation status in triple negative breast cancer is needed to determine the true mutation rate.
Introduction
Triple negative breast cancers, defined by the lack of
estrogen receptor (ER), progesterone receptor (PR) and
epidermal growth factor receptor 2 (Her2/cerbB2/
EGFR2) expression, account for 10 to 20% of all breast
carcinomas in Asian and Western populations [1-7], but
occur at much higher frequencies in individuals of
African descent [1-3,8]. These tumours are usually of
higher histological grade (Grade 3) [1,3,4,6,9,10] and are
associated with distinctive metastatic patterns [9,11],
shorter time to recurrence and earlier mortality
[9,11,12]. Recent focus on this breast cancer subtype
relates to resistance to endocrine and anti-HER2 direc-
ted therapy, phenotypic similarity to breast cancers in
BRCA1/2 mutation carriers and the development of
polyADP-ribose polymerase (PARP) inhibitors which
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Despite this breakthrough, sustained complete remis-
sions in advanced triple negative breast cancer are rare
and additional therapies directed against appropriate
molecular targets are needed.
EGFR is a receptor tyrosine kinase important in transdu-
cing extracellular signals from the cell surface to the cell
interior, mediating crucial processes such as cell prolifera-
tion, differentiation, migration and apoptosis. Dysregulated
expression of these receptors can lead to aberration of
homeostatic cellular processes, resulting in malignant
transformation of cells. Activating EGFR mutations have
been reported in cancers such as non-small cell lung
cancer (NSCLC) and head and neck cancers and are pre-
dictive of response to gefitinib or erlotinib therapy [13-15].
EGFR protein is expressed in 30% to 52% of triple negative
breast cancers [7,16,17] and up to 60% of the closely
related basal-like breast cancers and is associated with
poor prognosis [18-21]. These observations are the basis
for a number of ongoing clinical trials which are exploring
the role of monoclonal antibodies against EGFR such as
cetuximab and EGFR tyrosine kinase inhibitors such as
erlotinib in triple negative breast cancer.
Many mutations in the EGFR gene have been reported
in NSCLC but only a few have been validated, either from
in vitro studies or from tumour responses in NSCLC
patients, to be associated with responses to EGFR tyrosine
kinase drugs [13,14]. These mutations are usually found in
exons 18, 19, 20 and 21, and include missense substitu-
tions such as G719A/S and L858R and deletions like
E746 to A750 (removal of amino acids Glucine-Leucine-
Arginine-Glucine-Alanine (ELREA)) which are associated
with sensitivity to tyrosine kinase inhibitors [13,14]. Muta-
tions associated with resistance to EGFR tyrosine kinase
inhibitors are D761Y [22] and T790M [23,24]. We sought
to determine whether such mutations exist in triple nega-
tive breast cancers, the results of which may help to select
patients suitable for inclusion in clinical trials evaluating
the role of anti-EGFR directed therapies in this condition.
In this study, we report that 8 of 70 samples (11.4%)
of triple negative breast cancers harbor EGFR mutations,
including exon 19 deletions, inversions and exon 21
missense substitutions, which may predict sensitivity to
EGFR tyrosine kinase drugs, thus suggesting a rationale
for the clinical applicability of detecting EGFR mutations
in these tumours, and potential use of EGFR tyrosine
kinase inhibitor therapy.
Materials and methods
Histopathology and immunohistochemical review
Seventy archival paraffinised samples of triple negative
breast cancer, derived from a cohort of 653 invasive triple
negative breast tumours diagnosed at the Department of
Pathology, Singapore General Hospital, were chosen for
genomic EGFR mutation analysis. Triple negative status
of these tumours was confirmed by negative ER, PR, and
cerbB2 immunostaining. Briefly, paraffin sections were
stained for ER using Neomarker RM9101-S (1:50 dilu-
tion), PR using Neomarker RM9102-S (1:200 dilution)
and cerbB2 using Neomarker RM9103-S (1:200 dilution).
Antigen retrieval was performed by heating in 0.01 M
Tris EDTA pH9 using a microwave (Milestone T/T
mega). The detection system used was Dako Envision
Detection kit (K5007). For the purposes of this study, ER
and PR staining was considered positive when at least
10% of tumour cells displayed a minimum of 2+ nuclear
staining while cerbB2 was considered positive if at least
30% of tumour cells showed 3+ cell membrane staining.
A borderline/equivocal result was given for cerbB2 when
at least 10% of tumour cells demonstrated 2+ cytoplasmic
membrane staining. Tumours that failed to fulfill any of
the above criteria were considered triple negative.
Anti-EGFR monoclonal clone E30 (M7239, Dako,
Glostrup, Denmark) was used at a dilution of 1:50. EGFR
cytoplasmic membrane positivity was considered positive
EGFR staining. Staining intensity was scored as 0 (no
staining), 1+ (weak), 2+ (moderate) and 3+ (strong). The
immunohistochemical staining profile of the 653 invasive
triple negative breast tumours from which 70 breast
tumour tissues used for EGFR mutational analysis were
randomly selected from, is shown in Table 1. Ethics
approval had been obtained from the Institutional Review
Board, Singapore General Hospital. Samples were anon-
ymised with waiver of informed consent.
Mutation analysis
Representative unstained, formalin-fixed and paraffin-
embedded (FFPE) tumour sections were macro-dissected
to ensure purity of at least 70% invasive carcinoma cells
and without the presence of any normal breast epithelial
cells. Genomic DNA was extracted using QIAamp DNA
extraction kit for FFPE tissues (Qiagen, Hilden, Ger-
many) according to the manufacturer’sp r o t o c o lb u t
with slight modifications. Briefly, paraffin was removed
using xylene and residual xylene removed with ethanol.
Buffer ATL was added to the deparaffinised tissue and
heated at 98°C for 15 minutes [25,26] and cooled to
Table 1 Immunohistochemical profile of EGFR IHC
staining in 653 triple negative breast tumours
EGFR IHC staining Number of cases (Percentage)
Negative (0) 455 (70%)
Weak (1+) 159 (24%)
Moderate (2+) 24 (4%)
Strong (3+) 15 (2%)
Total 653 (100%)
IHC, immunohistochemical.
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tissue and incubated at 56°C for 16 hours. Afterward,
the tissue mixture was incubated at 90°C for one hour
and cooled to room temperature. Buffer AL was then
added and the following wash steps were performed
according to manufacturer’s instructions. DNA yield and
purity was quantitated and assessed using the Nanodrop
(Thermo Fisher Scientific, Waltham, MA, USA).
Polymerase chain reaction (PCR) was then performed
for all DNA samples using primers designed to amplify
exons 18, 19, 20 and 21 of the EGFR gene. Primer
sequences are shown in Table 2. Amplification reactions
were set up using reagents included in the Taq PCR Core
Kit (Qiagen), in accordance with the manufacturer’sp r o t o -
col. Essentially, each PCR reaction consisted of 1× PCR
buffer, 0.2 mM dNTP, 0.3 uM forward and reverse pri-
mers, 1.25 U Taq DNA polymerase and 250 ng of genomic
DNA in a total volume of 50 ul. The PCR cycling program
was as follows: (1) 94°C for 4 minutes (1 cycle), (2) 94°C
for 1 minute, 60°C for 1 minute, 72°C for 1 minute
(40 cycles) and (3) 72°C for 10 minutes (1 cycle). Non-
template (DNA) control represented the negative control
and was included in every PCR run.
PCR products were analysed by performing electrophor-
esis on a 2% agarose gel stained with ethidium bromide.
PCR products were purified using Qiagen PCR Purifica-
tion Kit (Qiagen). The purified PCR amplicons were
sequenced by 1
st BASE Pte Ltd (Singapore). Sequencing
was carried out in both forward and reverse directions.
DNA sequences were analysed using the National Center
for Biotechnology Information Human EGFR gene
sequence (mRNA Reference sequence NM_005228) and
BLAST software. EGFR mutations detected in the initial
round of sequencing were confirmed by subsequent
rounds of independent polymerase chain reaction and
sequencing reactions. Only mutations confirmed by subse-
quent rounds are reported. Cases found to harbor EGFR
mutations were checked against the corresponding normal
benign breast tissue consisting of at least 50% of epithelial
cells to determine if mutations were somatic or germline.
Results
Tumour characteristics
Clinicopathological data for the 70 cases of triple nega-
tive breast cancers are shown in Table 3. The median
patient age was 57 (range 38 to 78 years) and the
patient cohort was predominantly Chinese (59 of 70
cases) with nine patients being of Malay and two
patients of Indian ethnicity. Cases were predominantly
invasive ductal carcinomas (n =6 6 ) ,w i t ht w oc a s e so f
invasive lobular carcinoma, one case of papillary carci-
noma and one metaplastic carcinoma. The majority (53)
samples were of histological grade 3 with 15 cases of
grade 2, and two cases which were grade 1. Sixteen
cases showed trabecular growth patterns while the
remaining five cases demonstrated syncytial growth.
The median tumour size was 34.9 mm (range 1.5 mm
to 125 mm), 28 cases were associated with lymphovas-
cular invasion, and 34 patients had axillary lymph node
involvement.
Genomic DNA was extracted from 70 cases of triple
negative breast cancers. Successful PCR and good
sequencing data were obtained in all samples except 7
samples, 6 samples and 14 samples that failed to amplify
for Exon 18, 21 and 20, respectively. EGFR immunohis-
tochemical staining results are shown in Figure 1.
Detection of EGFR mutations
Several different mutations located in different exons
were found in triple negative breast cancer (Table 4).
Overall, 8 of 70 cases (11.4%) of triple negative breast
cancers showed heterozygous exon 19 deletions or exon
21 missense substitution mutations. Notably, 4 of 70
samples (5.8%) had in-frame deletions in exon 19, where
2 samples (2.9%) demonstrated 24 bp nucleotide dele-
tions at mRNA coding sequence position 2254 to 2277,
resulting in removal of eight amino acids Serine-Pro-
line-Lysine-Alanine-Asparagine-Lysine-Glutamic acid-
Isoleucine (SPKANKEI) at codons 752 to 759 (del S752
to I759) (Figure 2A, B) and the other two samples
(2.9%) had a 15 bp nucleotide deletion at mRNA coding
sequence positions 2236 to 2250, with the deletion of
five amino acids Glucine-Leucine-Arginine-Glucine-Ala-
nine (ELREA) from codons 746 to 750 (del E746 to
A750) (Figure 2C, D). We also observed an exchange of
positions of the double strands in the EGFR exon 19
gene, which was accompanied by gene inversion in one
sample (Figure 3). Corresponding normal benign breast
tissue of all the above cancers harboring mutations did
not disclose any abnormalities.
Table 2 Primer sequences
Exon Forward Primer Reverse Primer PCR product size (bp)
Exon 18 CTGAGGTGACCCTTGTCTCTGTGTTCTT AGAGGCCTGTGCCAGGGACCTTA 186
Exon 19 [24] TCACTGGGCAGCATGTGGCA CAGCTGCCAGACATGAGAAA 241
Exon 20 CCATGCGAAGCCACACTGA CGTATCTCCCTTCCCTGATTACC 248
Exon 21 AGCAGGGTCTTCTCTGTTTCA TGACCTAAAGCCACCTCCTT 200
bp, base pairs; PCR, polymerase chain reaction.
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cancers included two different missense mutations: a T
to G substitution at mRNA coding sequence position
2573 resulting in a Leucine to Arginine change at codon
858 (L858R) in 1.5% of the triple negative breast cancers
(1 of 70 samples) (Figure 4). We also observed a mis-
sense substitution of a Threonine residue to an Isoleu-
cine at amino acid codon position 847, resulting from a
nucleotide substitution of C to T at mRNA coding
sequence position 2540 (2 of 70 samples). Similarly,
corresponding normal breast tissue of the above three
mutated cancer samples showed no mutations, confirm-
ing their somatic nature.
Additionally, at exon 18, we found a single nucleotide
polymorphism at mRNA coding sequence position 2175
(ACG to ACA) that led to no amino acid changes at
codon 725 (Threonine to Threonine) in 4.3% (3 of 70
samples) of the triple negative breast cancers (T725,
NCBI Single Nucleotide Polymorphism database,
rs55959834). Also, G to A single nucleotide polymorph-
ism at codon 787 (Glutamine to Glutamine) of exon 20
was found in 6 of the 70 (8.6%) triple negative breast
cancers samples (Q787, NCBI Single Nucleotide Poly-
morphism database, rs1050171). Corresponding normal
breast tissues revealed the same polymorphisms as
observed in the invasive cancers.
Our study also revealed that triple negative breast
tumours harboring EGFR mutations consisted of both
EGFR protein positive and negative-stained cases by
immunohistochemistry (Table 5).
Discussion
In this study, we report the presence of EGFR muta-
tions, notably exon 19 deletions and exon 21 missense
(L858R) mutations, in 11.8% of triple negative breast
cancers evaluated. All samples showed heterozygous
deletions, suggesting they are likely dominant and play a
role in tumourigenesis [13]. EGFR mutations have been
found to occur in 13% to 64% of all non-small cell lung
cancers [27] and exon 19 deletions and L858R muta-
tions account for >80% of all EGFR mutations detected
in NSCLC [27]. More significantly, there is a plethora of
studies demonstrating that patients with these exon 19
deletions and L858R mutations respond very well to
EGFR inhibitors in NSCLC, as summarized in several
reviews [27-29]. Exon 19 deletions and L858R mutations
cluster around the ATP-binding pocket of the kinase
domain and such mutations confer ligand-independent
activation and increased activation duration compared
to wild-type receptors [13,14,30,31]. In vitro studies
showed that exon 19 deleted mutants and L858R
mutant receptors appear to be more sensitive to gefiti-
nib inhibition as compared to wild type receptors
[13,14]. This could explain why NSCLC patients harbor-
ing such mutations respond better to EGFR tyrosine
kinase inhibitors (TKIs) than patients without such
mutations. Patients with exon 19 harboring deletions
were found to have longer survival following treatment
with gefitinib or erlotinib compared with those having
Table 3 Clinicopathological characteristics of triple
negative breast cancers studied in this cohort
Clinicopathological features Numbers
Age (years)
Mean 52
Minimum 38
Maximum 78
Tumour size (mm)
Mean 34.9 mm
Minimum 1.5 mm
Maximum 125 mm
Tumour grade
12
21 5
35 3
Histology
Invasive ductal carcinoma 66
Invasive lobular carcinoma 2
Papillary 1
Metaplastic 1
Growth pattern
Trabecular 38
Syncytial 32
Nuclear pleomorphism
Moderate 19
Marked 51
Lymphovascular invasion
Present 28
Absent 41
Not available 1
Axillary lymph node involvement
Involved 34
Not involved 31
Not available 5
Associated DCIS
Absent 19
Intermediate nuclear grade 28
High nuclear grade 11
Not available 12
DCIS, ductal carcinoma in situ.
Teng et al. Breast Cancer Research 2011, 13:R35
http://breast-cancer-research.com/content/13/2/R35
Page 4 of 9L858R mutations in NSCLC [32,33]; however, Marks et
al. reported no difference in survival between exon 19
deletions and L858R mutations in the absence of EGFR
targeted therapy [34].
Several variant types of exon 19 deletions have been
reported in NSCLC where the majority (65% to 75%) have
EGFR exon 19 deletions of the 15 bp type (ELREA) and
only a minority (1 to 1.5%) have 24 bp exon 19 deletions
(SPKANKEI) [35]. Conversely, in our triple negative breast
cancers, we discovered that both exon 19 type deletions
(del E746 to A750 and del S752 to I759) are seen at similar
frequencies. Correlative studies where exon 19 deletions
were found to predict good response to EGFR TKIs
mainly include the 15 bp deletion type, while 24 bp dele-
tion types were rarely included (probably due to its low
frequency) or at best, analysed as a group with the 15 bp
deletion mutant. To our best knowledge, there appear to
be no reports addressing differing sensitivity of different
EGFR exon 19 deletions to gefitinib or erlotinib therapy.
Future studies can be done to determine whether there is
a variation in sensitivity to EGFR TKIs between the 15 bp
deletion type and 24 bp deletion type.
Bhargava et al. reported no EGFR mutations in 11
EGFR-amplified sporadic breast tumours examined, out of
which eight tumours were triple negative [36]. In a group
of 47 metaplastic breast carcinomas which belonged to a
subset of basal-like breast cancers, no EGFR tyrosine
kinase mutations were identified as well; however, the
actual ER, PR and cerbB2 status of these tumours analysed
were not explicitly clarified [21]. Generali et al. also
reported no EGFR mutations in 42 sporadic breast
tumours (no selection for triple negative breast tumours)
[37]. In a study of 58 triple negative breast tumours from
Japanese patients, using Taqman genotyping assays against
14 known EGFR mutations including those for exon 19
deletions and L858R missense, EGFR mutations were also
not found [38]. However, Weber et al. detected a higher
rate of EGFR missense mutations in BRCA1/2 positive
tumours (45.8%) compared with sporadic breast cancers
(14.6%) [39]. BRCA1-linked breast tumours typically exhi-
bit triple negative expression (ER-/PR-/Her2-) [12],
Figure 1 Immunohistochemical staining of EGFR in triple negative breast cancers. (A) Negative EGFR expression (B) 1+ EGFR expression
(C) 2+ EGFR expression (D) 3+ EGFR expression.
Table 4 Summary of EGFR mutations detected in primary
tumours of triple negative breast cancers (n =8 )
Mutations Number of samples (%)
Exon 19
del E746 to A750 (15 bp deletion) 2/70 (2.9%)
del S752 to I759 (24 bp deletion) 2/70 (2.9%)
inversion of complementary strand 1/70 (1.5%)
Exon 21
L858R 1/70 (1.5%)
T847I 2/70 (2.9%)
Total 8/70 (11.4%)
Single nucleotide polymorphisms
Exon 18
T725T 3/70 (4.3%)
Exon 20
Q787Q 6/70 (8.6%)
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show similar histopathological features to basal-like/triple
negative breast cancers [42]. However, EGFR missense
mutations identified in the BRCA1/2 tumours were differ-
ent from those encountered in our triple negative breast
cancer study, possibly due to different patient selection
where the BRCA1/2 linkage of our study cohort is
unknown. The apparent differing findings of the above
reports with ours could suggest heterogenous EGFR geno-
mic instability in different breast cancer groups and raises
the need for selection of specific breast cancers for EGFR
mutation analysis. Different patient ethnicity and back-
grounds may also be a contributing factor to the contra-
dictory results seen in our predominantly Chinese cohort
with those of the Japanese study group.
The development of anti-EGFR directed therapy in triple
negative breast cancer has been supported by the availabil-
ity of some preclinical data. In vitro s t u d i e so ne f f e c t so f
EGFR inhibition in triple negative breast cancer cell lines
revealed that gefitinib inhibited EGFR phosphorylation,
which led to reduced signaling by the mitogen activated
protein kinase (MAPK) and Akt pathway and causing
cell cycle arrest at G1 phase [43]. In addition, gefitinib
enhanced chemotherapeutic response to both carboplatin
and docetaxel in these cells [43]. In a Phase II trial of erlo-
tinib in patients with advanced breast cancer, 2 of 69
patients had partial responses, one of which had triple-
negative histology [44]. Clinical studies are currently
underway to evaluate the efficacy of EGFR tyrosine kinase
inhibitors in patients with triple negative breast cancers.
Figure 2 Exon 19 deletions encountered in triple negative breast cancers. Diagrams A to D show nucleotide sequences of EGFR gene in
triple negative breast tumour specimens with heterozygous in-frame deletions within Exon 19 tyrosine kinase domain (double peaks). Tracings
in both (A, C) sense and (B, D) antisense directions. The wildtype sequence is shown in capital letters, while the deleted mutant sequence is in
lowercase letters. Deleted sequence is highlighted in red capital letters. (A, B) 24 bp deleted region of EGFR gene leading to removal of
SPKANKEI at codons 752 to 759. (C, D) 15 bp deleted region of EGFR resulting in deletion of ELREA at codons 746 to 750.
Figure 3 Exchange of positions of double strands in EGFR exon 19, accompanied by gene inversions.D i a g r a m sA and B show
nucleotide sequences of EGFR exon 19 gene in triple negative breast tumour specimens with heterozygous gene inversions of the
complementary strand (double peaks). Tracings in both (A) sense and (B) antisense directions. The wild type sequence is shown in black capital
letters, while the mutant sequence is in red lowercase letters. The complementary sequence of the mutant strand corresponds exactly to the
wild type sequence and the orientation is reversed. Note only a segment of the sequencing diagrams (reading sequence towards the end) of
the forward and reverse sequence is shown to demonstrate that the whole portion of exon 19 gene is inverted with exchange of the
complementary strands.
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between EGFR positive immunostaining and the pre-
sence of EGFR mutations. It appears that positive EGFR
protein expression does not predict the presence of
mutations in triple negative breast tumours; conversely,
mutations have been found in negative EGFR immunos-
tained breast tumours. Monoclonal antibodies recognize
extracellular epitopes of the EGFR and mutations in the
EGFR gene could confer structural conformational
changes that render them unrecognizable by the antibo-
dies; besides, there are also possibilities of mutations in
other exons of the EGFR that were not probed in our
study. Pinter et al. have described that EGFR mutations
in lung adenocarcinomas are not consistently accompa-
nied by EGFR protein positivity by standard immunohis-
tochemistry [45]. They reported that some of the EGFR
mutant patients with major clinical response to gefitinib
or erlotinib showed negative EGFR immunostaining
[45]. Other studies have also noted such disagreement
between EGFR immunoexpression and presence of
mutations detected via molecular diagnostic methods
[37,46]. These results suggest the importance of molecu-
lar diagnostic methods to identify EGFR mutations and
subsequently those who will benefit from EGFR inhibi-
tor therapy. Specific antibodies that can detect EGFR
mutants have been developed by Brevet et al., and could
be advantageous in early identification of candidates for
EGFR mutational analysis via molecular methods in the
near future [35].
The relatively small sample size used in this study ren-
ders it difficult to make significant statistical judgments.
Nevertheless, the identification of important EGFR
mutations in our randomly selected cases from the lar-
ger series of triple negative breast cancers highlights the
need to understand the frequency and type of EGFR
mutations in a larger cohort, in order to promote a dee-
per understanding of the prospective utility of screening
for EGFR mutations in relation to the therapeutic use of
EGFR tyrosine kinase inhibitors for triple negative breast
cancer in a clinical trial setting.
Conclusions
This study demonstrated existing EGFR mutations in a
relatively small study size of 70 triple negative breast can-
cers in a Singapore population (8 of 70 samples). Muta-
tions observed included EGFR exon 19 deletions (4 of 70
samples ) and EGFR exon 21 substitutions (3 of 70 sam-
ples), both of which are commonly found in NSCLC and
are good predictors of sensitivity to tyrosine kinase inhi-
bition therapy. This advocates the promising application
of gefitinib or erlotinib therapy in triple negative breast
cancer, where the need to find new tailored treatment is
critical. These findings also encourage larger scale pro-
spective trials to evaluate the need for EGFR mutation
screening for anti-EGFR treatment in triple negative
breast cancers. It is also apparent that EGFR positivity by
standard immunohistochemistry is not necessarily
accompanied by EGFR mutations, suggesting that mole-
cular diagnostic methods appear to be more important
for selection of potential prospective patients with triple
negative breast cancers who may benefit from EGFR inhi-
bitor therapy.
Figure 4 Exon 21 missense mutations seen in triple negative
breast cancers. (A, B) Diagrams show substitution of T to G at
mRNA coding nucleotide sequence 2573; leucine to arginine amino
acid change at codon 858 (L858R). (C, D) Substitution of C to T at
mRNA coding nucleotide sequence 2540, resulting in a threonine to
isoleucin substitution at amino acid codon position 847. Tracings in
both (A, C) sense and (B, D) antisense directions. The wild type
sequence is shown in capital letters, while the missense nucleotide
is highlighted in red lowercase letters.
Table 5 EGFR immunostaining scores for 8 samples with
EGFR mutations
Sample
no.
EGFR IHC
score
EGFR mutation
1 0 T847I (in frame deletion mutation)
2 0 T847I (in frame deletion mutation)
3 0 Inversion of complementary strand of
exon 19
4 3+ Del S752 to I759 (In frame deletion
mutation)
5 2+ L858R (Missense mutation)
6 1+ Del E746 to A750 (In frame deletion
mutation)
7 1+ Del E746 to A750 (In frame deletion
mutation)
8 0 Del S752 to I759 (In frame deletion
mutation)
IHC, immunohistochemical.
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